Amneal Pharmaceuticals (AMRX) Change in Account Payables (2017 - 2026)

Amneal Pharmaceuticals' Change in Account Payables history runs 10 years deep, the most recent figure standing at -$41.1 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 3556.76% year-over-year to -$41.1 million in Q1 2026; TTM through Mar 2026 was -$39.0 million, a 181.65% decrease from a year earlier, with the FY2025 full-year figure at $931000.0, down 98.29% from the prior year.
• Change in Account Payables declined to -$41.1 million in Q1 2026 per AMRX's latest filing, from -$2.2 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $34.1 million in Q4 2024 and bottomed at -$41.1 million in Q1 2026.
• The 5-year median for Change in Account Payables is $1.7 million (2023), against an average of $1.5 million.
• Across the five-year window, Change in Account Payables plunged 6605.33% in 2022 and soared 1493.61% in 2023, its largest moves.
• Year by year, Change in Account Payables stood at -$407000.0 in 2022, then surged by 1493.61% to $5.7 million in 2023, then surged by 501.23% to $34.1 million in 2024, then tumbled by 106.38% to -$2.2 million in 2025, then plunged by 1788.88% to -$41.1 million in 2026.
• Per Business Quant, the three latest AMRX Change in Account Payables figures stand at -$41.1 million (Q1 2026), -$2.2 million (Q4 2025), and -$2.2 million (Q3 2025).